Mixed Earnings for Trulieve and MannKind Signal Sector-Specific Volatility
Trulieve Cannabis and MannKind reported divergent fourth-quarter results, with Trulieve beating earnings expectations despite a revenue miss, while MannKind saw a significant revenue surge that failed to translate into an EPS beat. These results highlight the ongoing tension between top-line growth and operational profitability in the cannabis and biopharma sectors.